Global Bisphosphonate Drug Market
Global Bisphosphonate Drug Market

Bisphosphonate Drug Comprehensive Study by Type (Alendronate, Etidronate, Risedronate, Zoledronic Acid), Application (Post-menopausal osteoporosis, Bone Loss caused by Cancer Treatment, Complex Regional Pain Syndrome, Paget's disease), Administration Type (Oral, Intravenous Infusion, Intravenous Injection) Players and Region - Global Market Outlook to 2024

Bisphosphonate Drug Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Oct 2019 Edition 202 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

Bisphosphonates drug is used to treat and prevent bone-related conditions. Bisphosphonates drugs are expected to grow exponentially during the forecast period owing to the increasing demand for the prevention and treatment of osteoporosis in postmenopausal women and for the treatment of Pagetís disease of bone. Also in anticancer treatment particularly for metastatic bone cancer and multiple myeloma bisphosphonate drugs are used.

The market study is being classified by Type (Alendronate, Etidronate, Risedronate and Zoledronic Acid), by Application (Post-menopausal osteoporosis, Bone Loss caused by Cancer Treatment, Complex Regional Pain Syndrome and Paget's disease) and major geographies with country level break-up.

Sanofi-Aventis SA (France), Immunomedics, Inc. (United States), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Progenics Pharmaceuticals, Inc. (United States), EUSA Pharma, Inc. (United States), Cell Genesys Inc. (United States), Dendreon Corporation (United States), Amgen Inc. (United States), Medimmune, LLC (United States) and AstraZeneca PLC (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Abbott Laboratories (United States), Genentech Inc. (United States), ALZA Corporation (United States), Spectrum Pharmaceuticals, Inc. (United States) and GlaxoSmithKline Plc (United Kingdom).

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Bisphosphonate Drug market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Bisphosphonate Drug market by Type, Application and Region.

On the basis of geography, the market of Bisphosphonate Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Geriatric Population and Changing Lifestyle Globally
  • Increasing Expenditure in the Healthcare Industry

Market Trend
  • Bisphosphonate Drug is Prescribed for Treatment of Osteoporosis

Restraints
  • High Cost associated with Drug

Opportunities
  • Increasing Research and Development Activites related to Drugs
  • Increasing Incidence of Menopausal in Women
  • Increasing Awareness of Bisphosphonate Drug

Challenges
  • Side Effects of the Drug such as Nausea, Abdominal Pain and Loose Bowel Movements


Market Leaders and their expansionary development strategies
In October 2019, Lantheus Holdings, Inc and Progenics Pharmaceuticals, Inc. announced a definitive agreement for Lantheus to acquire Progenics in an all-stock transaction. The combination of Lantheus and Progenics forms an innovative company with a diversified diagnostic and therapeutics portfolio.



Key Target Audience
Bisphosphonate Drug Manufacturers, Distributors/Traders/Wholesalers, Subcomponent Manufacturers, Industry Association and Downstream Vendors

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Alendronate
  • Etidronate
  • Risedronate
  • Zoledronic Acid
By Application
  • Post-menopausal osteoporosis
  • Bone Loss caused by Cancer Treatment
  • Complex Regional Pain Syndrome
  • Paget's disease
By Administration Type
  • Oral
  • Intravenous Infusion
  • Intravenous Injection

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Geriatric Population and Changing Lifestyle Globally
      • 3.2.2. Increasing Expenditure in the Healthcare Industry
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of the Drug such as Nausea, Abdominal Pain and Loose Bowel Movements
    • 3.4. Market Trends
      • 3.4.1. Bisphosphonate Drug is Prescribed for Treatment of Osteoporosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bisphosphonate Drug, by Type, Application, Administration Type and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Bisphosphonate Drug (Value)
      • 5.2.1. Global Bisphosphonate Drug by: Type (Value)
        • 5.2.1.1. Alendronate
        • 5.2.1.2. Etidronate
        • 5.2.1.3. Risedronate
        • 5.2.1.4. Zoledronic Acid
      • 5.2.2. Global Bisphosphonate Drug by: Application (Value)
        • 5.2.2.1. Post-menopausal osteoporosis
        • 5.2.2.2. Bone Loss caused by Cancer Treatment
        • 5.2.2.3. Complex Regional Pain Syndrome
        • 5.2.2.4. Paget's disease
      • 5.2.3. Global Bisphosphonate Drug by: Administration Type (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Intravenous Infusion
        • 5.2.3.3. Intravenous Injection
      • 5.2.4. Global Bisphosphonate Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Bisphosphonate Drug (Volume)
      • 5.3.1. Global Bisphosphonate Drug by: Type (Volume)
        • 5.3.1.1. Alendronate
        • 5.3.1.2. Etidronate
        • 5.3.1.3. Risedronate
        • 5.3.1.4. Zoledronic Acid
      • 5.3.2. Global Bisphosphonate Drug by: Application (Volume)
        • 5.3.2.1. Post-menopausal osteoporosis
        • 5.3.2.2. Bone Loss caused by Cancer Treatment
        • 5.3.2.3. Complex Regional Pain Syndrome
        • 5.3.2.4. Paget's disease
      • 5.3.3. Global Bisphosphonate Drug by: Administration Type (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Intravenous Infusion
        • 5.3.3.3. Intravenous Injection
      • 5.3.4. Global Bisphosphonate Drug Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Bisphosphonate Drug (Price)
      • 5.4.1. Global Bisphosphonate Drug by: Type (Price)
  • 6. Bisphosphonate Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi-Aventis SA (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Immunomedics, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Progenics Pharmaceuticals, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. EUSA Pharma, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cell Genesys Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Dendreon Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Amgen Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Medimmune, LLC (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. AstraZeneca PLC (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Bisphosphonate Drug Sale, by Type, Application, Administration Type and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Bisphosphonate Drug (Value)
      • 7.2.1. Global Bisphosphonate Drug by: Type (Value)
        • 7.2.1.1. Alendronate
        • 7.2.1.2. Etidronate
        • 7.2.1.3. Risedronate
        • 7.2.1.4. Zoledronic Acid
      • 7.2.2. Global Bisphosphonate Drug by: Application (Value)
        • 7.2.2.1. Post-menopausal osteoporosis
        • 7.2.2.2. Bone Loss caused by Cancer Treatment
        • 7.2.2.3. Complex Regional Pain Syndrome
        • 7.2.2.4. Paget's disease
      • 7.2.3. Global Bisphosphonate Drug by: Administration Type (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Intravenous Infusion
        • 7.2.3.3. Intravenous Injection
      • 7.2.4. Global Bisphosphonate Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Bisphosphonate Drug (Volume)
      • 7.3.1. Global Bisphosphonate Drug by: Type (Volume)
        • 7.3.1.1. Alendronate
        • 7.3.1.2. Etidronate
        • 7.3.1.3. Risedronate
        • 7.3.1.4. Zoledronic Acid
      • 7.3.2. Global Bisphosphonate Drug by: Application (Volume)
        • 7.3.2.1. Post-menopausal osteoporosis
        • 7.3.2.2. Bone Loss caused by Cancer Treatment
        • 7.3.2.3. Complex Regional Pain Syndrome
        • 7.3.2.4. Paget's disease
      • 7.3.3. Global Bisphosphonate Drug by: Administration Type (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Intravenous Infusion
        • 7.3.3.3. Intravenous Injection
      • 7.3.4. Global Bisphosphonate Drug Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Bisphosphonate Drug (Price)
      • 7.4.1. Global Bisphosphonate Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bisphosphonate Drug: by Type(USD Million)
  • Table 2. Bisphosphonate Drug Alendronate , by Region USD Million (2013-2018)
  • Table 3. Bisphosphonate Drug Etidronate , by Region USD Million (2013-2018)
  • Table 4. Bisphosphonate Drug Risedronate , by Region USD Million (2013-2018)
  • Table 5. Bisphosphonate Drug Zoledronic Acid , by Region USD Million (2013-2018)
  • Table 6. Bisphosphonate Drug: by Application(USD Million)
  • Table 7. Bisphosphonate Drug Post-menopausal osteoporosis , by Region USD Million (2013-2018)
  • Table 8. Bisphosphonate Drug Bone Loss caused by Cancer Treatment , by Region USD Million (2013-2018)
  • Table 9. Bisphosphonate Drug Complex Regional Pain Syndrome , by Region USD Million (2013-2018)
  • Table 10. Bisphosphonate Drug Paget's disease , by Region USD Million (2013-2018)
  • Table 11. Bisphosphonate Drug: by Administration Type(USD Million)
  • Table 12. Bisphosphonate Drug Oral , by Region USD Million (2013-2018)
  • Table 13. Bisphosphonate Drug Intravenous Infusion , by Region USD Million (2013-2018)
  • Table 14. Bisphosphonate Drug Intravenous Injection , by Region USD Million (2013-2018)
  • Table 15. South America Bisphosphonate Drug, by Country USD Million (2013-2018)
  • Table 16. South America Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 17. South America Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 18. South America Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 19. Brazil Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 20. Brazil Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 21. Brazil Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 22. Argentina Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 23. Argentina Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 24. Argentina Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 25. Rest of South America Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 26. Rest of South America Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 27. Rest of South America Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 28. Asia Pacific Bisphosphonate Drug, by Country USD Million (2013-2018)
  • Table 29. Asia Pacific Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 30. Asia Pacific Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 31. Asia Pacific Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 32. China Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 33. China Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 34. China Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 35. Japan Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 36. Japan Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 37. Japan Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 38. India Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 39. India Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 40. India Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 41. South Korea Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 42. South Korea Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 43. South Korea Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 44. Taiwan Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 45. Taiwan Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 46. Taiwan Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 47. Australia Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 48. Australia Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 49. Australia Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 50. Rest of Asia-Pacific Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 51. Rest of Asia-Pacific Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 52. Rest of Asia-Pacific Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 53. Europe Bisphosphonate Drug, by Country USD Million (2013-2018)
  • Table 54. Europe Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 55. Europe Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 56. Europe Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 57. Germany Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 58. Germany Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 59. Germany Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 60. France Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 61. France Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 62. France Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 63. Italy Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 64. Italy Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 65. Italy Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 66. United Kingdom Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 67. United Kingdom Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 68. United Kingdom Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 69. Netherlands Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 70. Netherlands Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 71. Netherlands Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 72. Rest of Europe Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 73. Rest of Europe Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 74. Rest of Europe Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 75. MEA Bisphosphonate Drug, by Country USD Million (2013-2018)
  • Table 76. MEA Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 77. MEA Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 78. MEA Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 79. Middle East Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 80. Middle East Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 81. Middle East Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 82. Africa Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 83. Africa Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 84. Africa Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 85. North America Bisphosphonate Drug, by Country USD Million (2013-2018)
  • Table 86. North America Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 87. North America Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 88. North America Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 89. United States Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 90. United States Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 91. United States Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 92. Canada Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 93. Canada Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 94. Canada Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 95. Mexico Bisphosphonate Drug, by Type USD Million (2013-2018)
  • Table 96. Mexico Bisphosphonate Drug, by Application USD Million (2013-2018)
  • Table 97. Mexico Bisphosphonate Drug, by Administration Type USD Million (2013-2018)
  • Table 98. Bisphosphonate Drug Sales: by Type(K Unit)
  • Table 99. Bisphosphonate Drug Sales Alendronate , by Region K Unit (2013-2018)
  • Table 100. Bisphosphonate Drug Sales Etidronate , by Region K Unit (2013-2018)
  • Table 101. Bisphosphonate Drug Sales Risedronate , by Region K Unit (2013-2018)
  • Table 102. Bisphosphonate Drug Sales Zoledronic Acid , by Region K Unit (2013-2018)
  • Table 103. Bisphosphonate Drug Sales: by Application(K Unit)
  • Table 104. Bisphosphonate Drug Sales Post-menopausal osteoporosis , by Region K Unit (2013-2018)
  • Table 105. Bisphosphonate Drug Sales Bone Loss caused by Cancer Treatment , by Region K Unit (2013-2018)
  • Table 106. Bisphosphonate Drug Sales Complex Regional Pain Syndrome , by Region K Unit (2013-2018)
  • Table 107. Bisphosphonate Drug Sales Paget's disease , by Region K Unit (2013-2018)
  • Table 108. Bisphosphonate Drug Sales: by Administration Type(K Unit)
  • Table 109. Bisphosphonate Drug Sales Oral , by Region K Unit (2013-2018)
  • Table 110. Bisphosphonate Drug Sales Intravenous Infusion , by Region K Unit (2013-2018)
  • Table 111. Bisphosphonate Drug Sales Intravenous Injection , by Region K Unit (2013-2018)
  • Table 112. South America Bisphosphonate Drug Sales, by Country K Unit (2013-2018)
  • Table 113. South America Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 114. South America Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 115. South America Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 116. Brazil Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 117. Brazil Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 118. Brazil Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 119. Argentina Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 120. Argentina Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 121. Argentina Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 122. Rest of South America Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 123. Rest of South America Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 124. Rest of South America Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 125. Asia Pacific Bisphosphonate Drug Sales, by Country K Unit (2013-2018)
  • Table 126. Asia Pacific Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 127. Asia Pacific Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 128. Asia Pacific Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 129. China Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 130. China Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 131. China Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 132. Japan Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 133. Japan Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 134. Japan Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 135. India Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 136. India Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 137. India Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 138. South Korea Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 139. South Korea Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 140. South Korea Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 141. Taiwan Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 142. Taiwan Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 143. Taiwan Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 144. Australia Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 145. Australia Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 146. Australia Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 147. Rest of Asia-Pacific Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 148. Rest of Asia-Pacific Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 149. Rest of Asia-Pacific Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 150. Europe Bisphosphonate Drug Sales, by Country K Unit (2013-2018)
  • Table 151. Europe Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 152. Europe Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 153. Europe Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 154. Germany Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 155. Germany Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 156. Germany Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 157. France Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 158. France Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 159. France Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 160. Italy Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 161. Italy Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 162. Italy Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 163. United Kingdom Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 164. United Kingdom Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 165. United Kingdom Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 166. Netherlands Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 167. Netherlands Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 168. Netherlands Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 169. Rest of Europe Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 170. Rest of Europe Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 171. Rest of Europe Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 172. MEA Bisphosphonate Drug Sales, by Country K Unit (2013-2018)
  • Table 173. MEA Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 174. MEA Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 175. MEA Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 176. Middle East Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 177. Middle East Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 178. Middle East Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 179. Africa Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 180. Africa Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 181. Africa Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 182. North America Bisphosphonate Drug Sales, by Country K Unit (2013-2018)
  • Table 183. North America Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 184. North America Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 185. North America Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 186. United States Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 187. United States Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 188. United States Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 189. Canada Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 190. Canada Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 191. Canada Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 192. Mexico Bisphosphonate Drug Sales, by Type K Unit (2013-2018)
  • Table 193. Mexico Bisphosphonate Drug Sales, by Application K Unit (2013-2018)
  • Table 194. Mexico Bisphosphonate Drug Sales, by Administration Type K Unit (2013-2018)
  • Table 195. Bisphosphonate Drug: by Type(USD/Units)
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Bisphosphonate Drug: by Type(USD Million)
  • Table 208. Bisphosphonate Drug Alendronate , by Region USD Million (2019-2024)
  • Table 209. Bisphosphonate Drug Etidronate , by Region USD Million (2019-2024)
  • Table 210. Bisphosphonate Drug Risedronate , by Region USD Million (2019-2024)
  • Table 211. Bisphosphonate Drug Zoledronic Acid , by Region USD Million (2019-2024)
  • Table 212. Bisphosphonate Drug: by Application(USD Million)
  • Table 213. Bisphosphonate Drug Post-menopausal osteoporosis , by Region USD Million (2019-2024)
  • Table 214. Bisphosphonate Drug Bone Loss caused by Cancer Treatment , by Region USD Million (2019-2024)
  • Table 215. Bisphosphonate Drug Complex Regional Pain Syndrome , by Region USD Million (2019-2024)
  • Table 216. Bisphosphonate Drug Paget's disease , by Region USD Million (2019-2024)
  • Table 217. Bisphosphonate Drug: by Administration Type(USD Million)
  • Table 218. Bisphosphonate Drug Oral , by Region USD Million (2019-2024)
  • Table 219. Bisphosphonate Drug Intravenous Infusion , by Region USD Million (2019-2024)
  • Table 220. Bisphosphonate Drug Intravenous Injection , by Region USD Million (2019-2024)
  • Table 221. South America Bisphosphonate Drug, by Country USD Million (2019-2024)
  • Table 222. South America Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 223. South America Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 224. South America Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 225. Brazil Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 226. Brazil Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 227. Brazil Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 228. Argentina Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 229. Argentina Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 230. Argentina Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 231. Rest of South America Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 232. Rest of South America Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 233. Rest of South America Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 234. Asia Pacific Bisphosphonate Drug, by Country USD Million (2019-2024)
  • Table 235. Asia Pacific Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 236. Asia Pacific Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 237. Asia Pacific Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 238. China Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 239. China Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 240. China Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 241. Japan Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 242. Japan Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 243. Japan Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 244. India Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 245. India Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 246. India Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 247. South Korea Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 248. South Korea Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 249. South Korea Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 250. Taiwan Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 251. Taiwan Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 252. Taiwan Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 253. Australia Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 254. Australia Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 255. Australia Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 256. Rest of Asia-Pacific Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 257. Rest of Asia-Pacific Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 258. Rest of Asia-Pacific Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 259. Europe Bisphosphonate Drug, by Country USD Million (2019-2024)
  • Table 260. Europe Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 261. Europe Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 262. Europe Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 263. Germany Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 264. Germany Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 265. Germany Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 266. France Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 267. France Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 268. France Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 269. Italy Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 270. Italy Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 271. Italy Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 272. United Kingdom Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 273. United Kingdom Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 274. United Kingdom Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 275. Netherlands Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 276. Netherlands Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 277. Netherlands Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 278. Rest of Europe Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 279. Rest of Europe Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 280. Rest of Europe Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 281. MEA Bisphosphonate Drug, by Country USD Million (2019-2024)
  • Table 282. MEA Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 283. MEA Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 284. MEA Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 285. Middle East Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 286. Middle East Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 287. Middle East Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 288. Africa Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 289. Africa Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 290. Africa Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 291. North America Bisphosphonate Drug, by Country USD Million (2019-2024)
  • Table 292. North America Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 293. North America Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 294. North America Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 295. United States Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 296. United States Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 297. United States Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 298. Canada Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 299. Canada Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 300. Canada Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 301. Mexico Bisphosphonate Drug, by Type USD Million (2019-2024)
  • Table 302. Mexico Bisphosphonate Drug, by Application USD Million (2019-2024)
  • Table 303. Mexico Bisphosphonate Drug, by Administration Type USD Million (2019-2024)
  • Table 304. Bisphosphonate Drug Sales: by Type(K Unit)
  • Table 305. Bisphosphonate Drug Sales Alendronate , by Region K Unit (2019-2024)
  • Table 306. Bisphosphonate Drug Sales Etidronate , by Region K Unit (2019-2024)
  • Table 307. Bisphosphonate Drug Sales Risedronate , by Region K Unit (2019-2024)
  • Table 308. Bisphosphonate Drug Sales Zoledronic Acid , by Region K Unit (2019-2024)
  • Table 309. Bisphosphonate Drug Sales: by Application(K Unit)
  • Table 310. Bisphosphonate Drug Sales Post-menopausal osteoporosis , by Region K Unit (2019-2024)
  • Table 311. Bisphosphonate Drug Sales Bone Loss caused by Cancer Treatment , by Region K Unit (2019-2024)
  • Table 312. Bisphosphonate Drug Sales Complex Regional Pain Syndrome , by Region K Unit (2019-2024)
  • Table 313. Bisphosphonate Drug Sales Paget's disease , by Region K Unit (2019-2024)
  • Table 314. Bisphosphonate Drug Sales: by Administration Type(K Unit)
  • Table 315. Bisphosphonate Drug Sales Oral , by Region K Unit (2019-2024)
  • Table 316. Bisphosphonate Drug Sales Intravenous Infusion , by Region K Unit (2019-2024)
  • Table 317. Bisphosphonate Drug Sales Intravenous Injection , by Region K Unit (2019-2024)
  • Table 318. South America Bisphosphonate Drug Sales, by Country K Unit (2019-2024)
  • Table 319. South America Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 320. South America Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 321. South America Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 322. Brazil Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 323. Brazil Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 324. Brazil Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 325. Argentina Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 326. Argentina Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 327. Argentina Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 328. Rest of South America Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 329. Rest of South America Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 330. Rest of South America Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 331. Asia Pacific Bisphosphonate Drug Sales, by Country K Unit (2019-2024)
  • Table 332. Asia Pacific Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 333. Asia Pacific Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 334. Asia Pacific Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 335. China Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 336. China Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 337. China Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 338. Japan Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 339. Japan Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 340. Japan Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 341. India Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 342. India Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 343. India Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 344. South Korea Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 345. South Korea Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 346. South Korea Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 347. Taiwan Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 348. Taiwan Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 349. Taiwan Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 350. Australia Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 351. Australia Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 352. Australia Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 353. Rest of Asia-Pacific Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 354. Rest of Asia-Pacific Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 355. Rest of Asia-Pacific Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 356. Europe Bisphosphonate Drug Sales, by Country K Unit (2019-2024)
  • Table 357. Europe Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 358. Europe Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 359. Europe Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 360. Germany Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 361. Germany Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 362. Germany Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 363. France Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 364. France Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 365. France Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 366. Italy Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 367. Italy Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 368. Italy Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 369. United Kingdom Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 370. United Kingdom Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 371. United Kingdom Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 372. Netherlands Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 373. Netherlands Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 374. Netherlands Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 375. Rest of Europe Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 376. Rest of Europe Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 377. Rest of Europe Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 378. MEA Bisphosphonate Drug Sales, by Country K Unit (2019-2024)
  • Table 379. MEA Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 380. MEA Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 381. MEA Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 382. Middle East Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 383. Middle East Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 384. Middle East Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 385. Africa Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 386. Africa Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 387. Africa Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 388. North America Bisphosphonate Drug Sales, by Country K Unit (2019-2024)
  • Table 389. North America Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 390. North America Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 391. North America Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 392. United States Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 393. United States Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 394. United States Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 395. Canada Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 396. Canada Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 397. Canada Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 398. Mexico Bisphosphonate Drug Sales, by Type K Unit (2019-2024)
  • Table 399. Mexico Bisphosphonate Drug Sales, by Application K Unit (2019-2024)
  • Table 400. Mexico Bisphosphonate Drug Sales, by Administration Type K Unit (2019-2024)
  • Table 401. Bisphosphonate Drug: by Type(USD/Units)
  • Table 402. Research Programs/Design for This Report
  • Table 403. Key Data Information from Secondary Sources
  • Table 404. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bisphosphonate Drug: by Type USD Million (2013-2018)
  • Figure 5. Global Bisphosphonate Drug: by Application USD Million (2013-2018)
  • Figure 6. Global Bisphosphonate Drug: by Administration Type USD Million (2013-2018)
  • Figure 7. South America Bisphosphonate Drug Share (%), by Country
  • Figure 8. Asia Pacific Bisphosphonate Drug Share (%), by Country
  • Figure 9. Europe Bisphosphonate Drug Share (%), by Country
  • Figure 10. MEA Bisphosphonate Drug Share (%), by Country
  • Figure 11. North America Bisphosphonate Drug Share (%), by Country
  • Figure 12. Global Bisphosphonate Drug: by Type K Unit (2013-2018)
  • Figure 13. Global Bisphosphonate Drug: by Application K Unit (2013-2018)
  • Figure 14. Global Bisphosphonate Drug: by Administration Type K Unit (2013-2018)
  • Figure 15. South America Bisphosphonate Drug Share (%), by Country
  • Figure 16. Asia Pacific Bisphosphonate Drug Share (%), by Country
  • Figure 17. Europe Bisphosphonate Drug Share (%), by Country
  • Figure 18. MEA Bisphosphonate Drug Share (%), by Country
  • Figure 19. North America Bisphosphonate Drug Share (%), by Country
  • Figure 20. Global Bisphosphonate Drug: by Type USD/Units (2013-2018)
  • Figure 21. Global Bisphosphonate Drug share by Players 2018 (%)
  • Figure 22. Global Bisphosphonate Drug share by Players (Top 3) 2018(%)
  • Figure 23. Global Bisphosphonate Drug share by Players (Top 5) 2018(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Sanofi-Aventis SA (France) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi-Aventis SA (France) Revenue: by Geography 2018
  • Figure 27. Immunomedics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Immunomedics, Inc. (United States) Revenue: by Geography 2018
  • Figure 29. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis AG (Switzerland) Revenue: by Geography 2018
  • Figure 31. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2018
  • Figure 33. Progenics Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Progenics Pharmaceuticals, Inc. (United States) Revenue: by Geography 2018
  • Figure 35. EUSA Pharma, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. EUSA Pharma, Inc. (United States) Revenue: by Geography 2018
  • Figure 37. Cell Genesys Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Cell Genesys Inc. (United States) Revenue: by Geography 2018
  • Figure 39. Dendreon Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 40. Dendreon Corporation (United States) Revenue: by Geography 2018
  • Figure 41. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Amgen Inc. (United States) Revenue: by Geography 2018
  • Figure 43. Medimmune, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 44. Medimmune, LLC (United States) Revenue: by Geography 2018
  • Figure 45. AstraZeneca PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 46. AstraZeneca PLC (United Kingdom) Revenue: by Geography 2018
  • Figure 47. Global Bisphosphonate Drug: by Type USD Million (2019-2024)
  • Figure 48. Global Bisphosphonate Drug: by Application USD Million (2019-2024)
  • Figure 49. Global Bisphosphonate Drug: by Administration Type USD Million (2019-2024)
  • Figure 50. South America Bisphosphonate Drug Share (%), by Country
  • Figure 51. Asia Pacific Bisphosphonate Drug Share (%), by Country
  • Figure 52. Europe Bisphosphonate Drug Share (%), by Country
  • Figure 53. MEA Bisphosphonate Drug Share (%), by Country
  • Figure 54. North America Bisphosphonate Drug Share (%), by Country
  • Figure 55. Global Bisphosphonate Drug: by Type K Unit (2019-2024)
  • Figure 56. Global Bisphosphonate Drug: by Application K Unit (2019-2024)
  • Figure 57. Global Bisphosphonate Drug: by Administration Type K Unit (2019-2024)
  • Figure 58. South America Bisphosphonate Drug Share (%), by Country
  • Figure 59. Asia Pacific Bisphosphonate Drug Share (%), by Country
  • Figure 60. Europe Bisphosphonate Drug Share (%), by Country
  • Figure 61. MEA Bisphosphonate Drug Share (%), by Country
  • Figure 62. North America Bisphosphonate Drug Share (%), by Country
  • Figure 63. Global Bisphosphonate Drug: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Sanofi-Aventis SA (France)
  • Immunomedics, Inc. (United States)
  • Novartis AG (Switzerland)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Progenics Pharmaceuticals, Inc. (United States)
  • EUSA Pharma, Inc. (United States)
  • Cell Genesys Inc. (United States)
  • Dendreon Corporation (United States)
  • Amgen Inc. (United States)
  • Medimmune, LLC (United States)
  • AstraZeneca PLC (United Kingdom)
Additional players considered in the study are as follows:
Abbott Laboratories (United States) , Genentech Inc. (United States) , ALZA Corporation (United States) , Spectrum Pharmaceuticals, Inc. (United States) , GlaxoSmithKline Plc (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation